SynthesisBMC endocrine disorders2026
Prevalence of poor glycemic control in diabetic hypertensive patients: a systematic review and meta-analysis.
Synthesis in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPoor glycemic control is a significant public health issue, contributing to the development of complications, increasing healthcare costs, and quality of life. The objective of the meta-analysis is to estimate the prevalence of poor glycemic control and its prevalence according to diagnostic criteria in diabetic hypertensive patients. Findings will be critical in reducing the burden of poor glycemic control and complications.
methodsA systematic review and meta-analysis were conducted in accordance with the PRISMA 2020 guidelines. Three electronic databases (PubMed, Web of Science, and SCOPUS) were searched for studies published in English between January 2015 and January 2025. Primary studies assessed glycemic control among diabetic-hypertensive patients using one or more of the following: a fasting blood glucose (FBG) level (> 126 mg/dL, > 130 mg/dL, or > 130 mg/dL) and/or glycated hemoglobin A1C level (≥ 7%). Random-effects models (metaprop, REML) were used to estimate pooled prevalence. Heterogeneity, sensitivity test, subgroup analysis, and publication bias assessments were performed.
resultsIn this study, ten papers involving a total of 2552 individuals were utilized to derive the pooled estimate. The pooled prevalence of poor glycemic control was 59% (95%CI; 0.49-0.69). Based on diagnostic criteria the pooled prevalence of poor glycemic control in diabetic hypertensive patients was 46% (95%CI: 0.31-0.61), and 65% (95%CI; 0.54-0.76) for fasting blood glucose and glycosylated hemoglobin respectively. There is substantial heterogeneity but no significant publication bias on visual inspection of the forest plot.
conclusionAround two-third of study participants have poor glycemic control in diabetic hypertensive patients. This finding is important as a baseline for refining clinical guidelines and improving long-term outcomes for this high-risk group. Future researchers will evaluate effective interventions to improve glycemic control in diabetic hypertensive patients across diverse study settings. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.